All In Biotech

Drug Trial Radar · NCT05912244

A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma

A Phase II Study of IO102/IO103 and Nivolumab-relatlimab Fixed Dose Combination in Untreated, Unresectable Stage III/IV Melanoma

Last checked: Nov 20, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

43

Actual

Start

Jun 9, 2023

Primary completion

Jun 9, 2027

Study completion Jun 9, 2027

Sponsor

Lead sponsor
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
IO Biotech
First posted
Jun 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The researchers are doing this study to find out whether the study vaccines, IO102/IO103, given in combination with the standard-of-care drug combination, nivolumab and relatlimab, is a safe and effective treatment for people with untreated, unresectable melanoma.

Conditions

  • Melanoma

Interventions

  • IO102/IO103Drug

    IO102/IO103 will be administered subcutaneously on Days 1 and 15 of the first two 28-day cycles, and then on Day 1 only of subsequent cycles for two total years of treatment. Each vaccine contains 85ug.

  • Nivolumab-RelatlimabDrug

    Nivolumab-relatlimab will be administered as a single infusion 160mg relatlimab and nivolumab 480 mg for all participants. Both agents will be combined in a single fixed-dose combination (FDC) as an intravenous 30-minute infusion every four weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR)Time frame: 3 years

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Hartford Healthcare Alliance (Data Collection Only)

    Hartford, Connecticut

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

    Basking Ridge, New Jersey

  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

    Middletown, New Jersey

  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)

    Montvale, New Jersey

  • Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)

    Commack, New York

  • Memorial Sloan Kettering Westchester (All Protocol Activities)

    Harrison, New York

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    New York, New York

  • Memorial Sloan Kettering Nassau (Limited Protocol Activities)

    Uniondale, New York

  • Lehigh Valley Health Network (Data Collection Only)

    Allentown, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.